Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • AZD5363 in combination with fulvestrant in AKT1-mutant ER-positive metastatic breast cancer
    Meeting Abstract

    Smyth, L. M.; Oliveira, M.; Ciruelos, E.; Tamura, K.; El-Khoueiry, A.; Mita, A.; You, B.; Renouf, D. J.; Sablin, M. P.; Lluch, A.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer
    Meeting Abstract

    Sparano, J. A.; O'Neill, A.; Alpaugh, K.; Wolff, A. C.; Northfelt, D. W.; Dang, C.; Sledge, G. W. Jr.; Miller, K. D.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Immune profile of small HER2+ tumors in the APT trial
    Meeting Abstract

    Tolaney, S. M.; Barry, W.; Guo, H.; Dillon, D.; Tan, Y. B.; Fuhrman, K.; Osmani, W.; Getz, A.; Baltay, M.; Dang, C.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)
    Meeting Abstract

    Tripathy, D.; Sara, T.; Seidman, A. D.; Anders, C. K.; Ibrahim, N.; Rugo, H. S.; Twelves, C. J.; Diéras, V.; Müller, V.; Hannah, A.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Mucinous breast carcinomas: A genomically distinct subtype of estrogen receptor-positive invasive breast cancers
    Meeting Abstract

    Pareja, F.; Geyer, F. C.; Piscuoglio, S.; Selenica, P.; Kumar, R.; Lim, R. S.; Guerini-Rocco, E.; Marchio, C.; Mariani, O.; Ng, C. K. Y.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Bi-allelic alterations in homologous recombination (HR) DNA repair-related genes as the basis for HR defects in human cancers: A pan-cancer genomics and functional analysis
    Meeting Abstract

    Riaz, N.; Blecua, P.; Lim, R. S.; Shen, R.; Higginson, D. S.; Weinhold, N.; Norton, L.; Weigelt, B.; Powell, S. N.; Reis-Filho, J. S.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)
    Meeting Abstract

    Rugo, H. S.; Barry, W. T.; Moreno-Aspitia, A.; Lyss, A.; Huebner, L.; Mayer, E. L.; Naughton, M.; Layman, R. M.; Carey, L. A.; Somer, R. A.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor-positive breast cancer
    Meeting Abstract

    Krop, I.; Abramson, V.; Colleoni, M.; Traina, T.; Holmes, F.; Estevez, L.; Hart, L.; Awada, A.; Zamagni, C.; Morris, P.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab
    Meeting Abstract

    Krop, I. E.; Hillman, D.; Polley, M. Y.; Tanioka, M.; Parker, J.; Huebner, L.; Henry, N. L.; Tolaney, S. M.; Dang, C.; Harris, L.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Trajectory patterns of circulating tumor cells (CTC) in chemotherapy-treated metastatic breast cancer (MBC) patients predict poor clinical outcomes: CALGB 40502 (Alliance)/NCCTG N063H study
    Meeting Abstract

    Magbanua, M. J.; Hendrix, L.; Hyslop, T.; Barry, W. T.; Winer, E. P.; Hudis, C.; Toppmeyer, D.; Burnstein, H.; Qadir, M.; Ma, C.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save